Navigation Links
More intensive radiotherapy is better than less for localized prostate cancer
Date:2/25/2014

A radiotherapy regime involving higher doses of radiation is a better option than having lower doses for men with localised prostate cancer, the 10-year results of the largest trial of its kind have shown.

Having 37 rounds, or fractions, of radiotherapy at 74 Gray (Gy) compared with 32 fractions at 64 Gy controlled the disease more effectively and reduced the chance that men would need follow-up hormone-deprivation therapy, which can have long-term side-effects.

The findings, published in The Lancet Oncology today (Wednesday), come from the major RT01 phase III trial. The trial was led by Professor Dearnaley at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and was funded and conducted by the Medical Research Council Clinical Trials Unit at UCL. The study also involved several leading clinical research centres in the UK, New Zealand and Australia.

The study also demonstrated the overall effectiveness of radiotherapy for men with localised disease. Almost three quarters of men treated with either the more or less intensive radiotherapy regimes were still alive after 10 years.

Set up in 1998, the trial split 843 men with localised prostate cancer into two groups to compare the two doses of radiotherapy. Some 421 men had the less and 422 the more intensive treatment regimes. Both groups also had standard hormone-deprivation treatment alongside their radiotherapy.

The five-year results of the trial have previously shown the benefits of dose-escalated radiotherapy, and played an influential role in changing NICE guidance to recommend it in prostate cancer. Dose escalation is now the norm for localised prostate cancer in the UK.

The new 10-year results further strengthen the evidence for choosing dose-escalation radiotherapy, as well as showing the long-term benefits of the treatment.

After 10 years, 55 per cent of men on the 37-fraction regime, compared with 43 per cent of men on the 32-fraction regime, had survived without their disease progressing into a more hazardous form, as measured by the standard prostate-specific antigen (PSA) test. In each half of the study, 71 per cent of men were alive after 10 years and only 11 per cent had died from prostate cancer.

Men who received the higher dose were more likely to have side-effects associated with radiotherapy, but few men had severe side-effects. Receiving the higher dose reduced the need for follow-up hormone treatment, which also carries a risk of side-effects.

The trial did not show that men given dose-escalated radiotherapy live longer, but both groups of men lived much longer than expected. Almost three quarters of all the men in the study were still alive after 10 years, and of the 236 men who had died since treatment, only 91 had died of prostate cancer.

Study leader Professor David Dearnaley, Professor of Uro-Oncology at The Institute of Cancer Research, London, and Honorary Consultant at the Royal Marsden NHS Foundation Trust, said:

"Our study has proved that treating men with localised prostate cancer using higher doses of radiotherapy is more effective than a less intensive regime. The dose-escalated regime is safe in the long term, and reduces the chances that a cancer will return and men will require further hormone-deprivation treatment. The side-effects of hormone treatment do need to be balanced against those of the extra radiotherapy doses, but overall our study has shown men are better off after having the escalated regime, as is now the norm in the UK.

"Another key finding to come out of our study is that radiotherapy in general is both a safe and an effective treatment for localised prostate cancer. Almost three quarters of men treated with either the more or less intensive radiotherapy regimes are still alive after 10 years, and of the men who have died, less than half actually died from prostate cancer.

"Further refinements in radiotherapy techniques since our trial began have made treatment even safer and are very important as men with localised prostate cancer have such favourable long-term survival prospects."

Matthew Sydes, Senior Scientist and Statistician at the MRC Clinical Trials Unit at UCL, said:

"The RT01 trial has already changed how men with localised prostate cancer are treated. The current NICE guidelines recommend the use of the higher dose of radiotherapy, based on the five-year results of RT01. The trial also helped to develop guidelines on how to limit the radiation that organs near the tumour receive, and helped hospitals across the UK to introduce quality-assured conformal radiotherapy. It is now contributing to biological studies to help better understand the disease and the side-effects of radiotherapy."


'/>"/>

Contact: henry.french@icr.ac.uk
henry.french@icr.ac.uk
020-715-35312
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. Texas Children’s Hospital Launches Music Therapy Program for Babies in Neonatal Intensive Care Unit and Inpatient Rehabilitation
2. Halfway There Florida Announces the Opening of Intensive Outpatient Program in Delray Beach
3. Rates of infection in intensive care units in England show impressive fall
4. June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy
5. Multidisciplinary initiative reduces airway infection in pediatric intensive care patients
6. PR News Announces One-Day Boot Camp on Content Marketing; Intensive Sessions Will be Held June 18 in NYC
7. CLABSI prevention efforts result in up to 200,000 infections prevented in intensive care units
8. No greater death risk for children admitted to emergency out-of-hours intensive care
9. Four Intensive Sessions to Provide Practical Training on All Aspects of Operating an Insurance Exchange in AIS’s Virtual Conference
10. Nursing Shortage May Harm Infants in Intensive Care, Study Says
11. Scores that evaluate newborn intensive care units are inconsistent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... ... communities throughout the greater Cincinnati metropolitan area, is teaming up with the local ... families with children receiving treatment in nearby hospitals. , Ronald McDonald House of ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology: